VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review)

Samanta Taurone*, Filippo Galli, Alberto Signore, Enzo Agostinelli, Rudi A. J. O. Dierckx, Antonio Minni, Marcella Pucci, Marco Artico

*Bijbehorende auteur voor dit werk

Onderzoeksoutputpeer review

13 Citaten (Scopus)


Clinical trials using antiangiogenic drugs revealed their potential against cancer. Unfortunately, a large percentage of patients does not yet benefit from this therapeutic approach highlighting the need of diagnostic tools to non-invasively evaluate and monitor response to therapy. It would also allow to predict which kind of patient will likely benefit of antiangiogenic therapy. Reasons for treatment failure might be due to a low expression of the drug targets or prevalence of other pathways. Molecular imaging has been therefore explored as a diagnostic technique of choice. Since the vascular endothelial growth factor (VEGF/VEGFR) pathway is the main responsible of tumor angiogenesis, several new drugs targeting either the soluble ligand or its receptor to inhibit signaling leading to tumor regression could be involved. Up today, it is difficult to determine VEGF or VEGFR local levels and their non-invasive measurement in tumors might give insight into the available target for VEGF/VEGFR-dependent antiangiogenic therapies, allowing therapy decision making and monitoring of response.

Originele taal-2English
Pagina's (van-tot)437-447
Aantal pagina's11
TijdschriftInternational journal of oncology
Nummer van het tijdschrift2
StatusPublished - aug-2016

Citeer dit